This suppresses cell proliferation and causes apoptosis [5]. HER2 inhibitors (Trastuzumab, Ado-trastuzumab, Emtansine) inhibit the oncogenic properties of HER2 receptors in HER2-positive cancers and stimulate immune responses against HER2-amplified cancers [6]. This evidence concerns the gene ERBB2 and cancer.